Next Article in Journal
Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma
Next Article in Special Issue
A Fluorescence-Based Wireless Capsule Endoscopy System for Detecting Colorectal Cancer
Previous Article in Journal
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
Previous Article in Special Issue
Biobanking in Molecular Biomarker Research for the Early Detection of Cancer
Open AccessArticle

Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage

1
Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy
2
Università Vita-Salute San Raffaele, 20132 Milano, Italy
3
Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, 20133 Milano, Italy
4
Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Università degli Studi di Milano, 20157 Milano, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 870; https://doi.org/10.3390/cancers12040870
Received: 18 February 2020 / Revised: 12 March 2020 / Accepted: 1 April 2020 / Published: 3 April 2020
(This article belongs to the Special Issue Non-Invasive Early Detection of Cancers)
Due to the involvement of the endocannabinoid system (ECS) in cancer onset and progression and the less studied connection between ECS and bladder cancer, here an evaluation of the ECS modifications associated with bladder cancer is reported. Urine samples were collected from healthy volunteers and patients with bladder cancer at different grades. Endocannabinoids (ECs) and N-acylethanolamides (NAEs) were quantified by HPLC-MS/MS and results normalized for creatinine content. An increase in the urine concentrations of four ECs and NAEs analyzed was observed with a statistically significant increase in the arachidonoylethanolamide (AEA) and stearoylethanoamide (SEA) associated with bladder cancer. Receiver operating characteristic curves built with AEA and SEA data allowed the selection of 160 pg/mL for SEA (area under the curve (AUC) = 0.91, Selectivity (SE) 94%, Specificity (SP) 45%) and 8 pg/mL for AEA (AUC = 0.85, SE 94%, SP 61%) as the best cut-off values. Moreover, data from bladder cancer samples at different grades were derived from The Cancer Genome Atlas, and the expressions of thirteen different components of the “endocannabinoidome” were analyzed. Statistical analysis highlights significant variations in the expression of three enzymes involved in EC and NAE turnover in bladder cancer.
Keywords: bladder cancer; endocannabinoid system; endocannabinoid quantification; biomarkers bladder cancer; endocannabinoid system; endocannabinoid quantification; biomarkers
Show Figures

Graphical abstract

MDPI and ACS Style

Vago, R.; Ravelli, A.; Bettiga, A.; Casati, S.; Lavorgna, G.; Benigni, F.; Salonia, A.; Montorsi, F.; Orioli, M.; Ciuffreda, P.; Ottria, R. Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage. Cancers 2020, 12, 870.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop